The FDA is looking into whether Boehringer Ingelheim’ respiratory inhaler poses a greater risk of stroke. According to the FDA, the data submitted by the German drug manufacturer, shows that its Spiriva Handihaler poses a greater risk of stroke compared with a placebo. FDA said it has not yet analyzed the figures, which were compiled from 29 patient studies. The FDA has asked doctors to report any adverse patient results while it waits for more data from the company in June.
Admitted to practice law in all federal multidistrict litigation courts, the California State Bar and the Florida Bar. His philosophy is to provide aggressive, quality representations and seek fair compensation for individuals and their families who have suffered injury, death, or sexual abuse.
Comments for this article are closed.